NCT02737306View on ClinicalTrials.gov

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 14, 2017

Primary Completion Date

April 14, 2021

Study Completion Date

September 30, 2021

Conditions
Graft Vs Host Disease
Interventions
DRUG

PRO 140

PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

DRUG

Placebo

Placebo in parenteral solution.

Trial Locations (8)

19104

University of Pennsylvania, Philadelphia

26506

West Virginia University Medicine, Morgantown

27157

Wake Forest Baptist Health, Winston-Salem

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

48201

Barbara Ann Karmanos Cancer Institute, Detroit

55409

University of Minnesota, Minneapolis

60153

Loyola University Medical Center Cardinal Bernardin Cancer Center, Maywood

78229

Texas Transplant Institute Methodist Hospital, San Antonio

Sponsors

Lead Sponsor

CytoDyn, Inc.

Collaborators (1)

Amarex Clinical Research
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

CytoDyn, Inc.

INDUSTRY

NCT02737306 - A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation | Biotech Hunter | Biotech Hunter